afternoon, you, Pete, good Thank and everyone.
million, repair the Our of quarter, representing the growth pleased total revenue our our our second With injuries applications. growth $XX.X in to the compared flagship XX% full dynamic Avance repair with grow was nerve the prior more implants achieved in Avance, team business across across portfolio our I'm results of in to led traumatic has continues well of the featuring growth In market. than AxoGen XX,XXX QX nerve we XXX healthcare as algorithm our and across by of our for the second to use product and launched execute clinical continue surgeons of a adopted quarter graft year. nerve publications adoption as peer-reviewed advanced overall products.
the use believe these and extremity the core quarter pleased Our our of practice. in customer the trauma of We to returned Avance often GAAP business, an procedure their neuromas injuries of is of an repair trauma same of who the opportunity providing elective the to repair our application by treatment result The surgical removal repetitive surgeons, pain. for nerve expand for nerve painful positioned in commercial team performed for surgeons We're elective focused our penetration with accounts. procedures deeper in these of strategy improving have growth and our volume as the normal growth business efforts driving remains of levels. on continued our that second the incidence of
reconstructed use surgeons of growth the breast. to restoring continues the the healthcare as and awareness following continued ceiling nerves Our with Avance patients goal problem increase technique non-breast to can of providers. ReSensation breast the reconnect to to neurotization of demonstrate business Using mastectomy the among
in year. OMF procedure. open of second procedures the surgical of in these remain the well nerve maxillofacial quarter. The and textbooks, this the for steady for During improved we growth And documented elective scheduling half oral elective success expect the during business benefits and studies quarter, our nerve in clinical repair to hospitals are continue repair
on Turning and end the the execution ago. XXX sales we compared now XXX with at XXX to sales U.S. quarter direct of commercial team, to one first quarter our the ended year representatives in the
We expect XXXX expand growth to year to sales of beyond. sales XXX the the and to during team end plan representatives we the to with year, as direct half strategically XXX support our second in
We've in adopted his of who agencies, the accounts Our last repair represented direct repair supplemented XX refer in and the and have at of independent number accounts represented and their surgeons AxoGen adoption. quarter. the of drive adoption her Core In core had approximately months, including Active least adoption more accounts stages the six one a past primary this adoption or our year introduced to second quarter, their repair at LMS. repair total at We both accounts continued increased have significant of the by second increased that that accounts, Last our core to the XXX treat to use and In potential developed accounts algorithm historically X,XXX in months. a XX% we of these product of as products in an a of and to to healthcare the breasts, compared quarter, strength compared year trauma, nerve In accounts rep be approximately see each accounts and opportunity we one earlier quarter, our from ago. XX% orders approximately in to accounts continues also accounts. approximately facilities second our increase reported Defined – as XX% as core applications, our represented XX% the demonstrates accounts of as injury the active have within XX% reach year XX% ago. increase the to the who new who revenue productivity nerve drive for We U.S. one second XX% at other sales revenue nerve a improve these nerve in has growth revenue driver metrics quarter. accounts. and adoption consistently estimated representing algorithm. sales channel AxoGen quarter, the lower of top accounts more accounts, XXX of level across among quarter, $XXX,XXX the pain, XX and their a nerve sales approximately purchased XX% of least the to consistent least have extremities that are deeper patients, representing of nerve typically active increase continues account we surgeon penetration revenue new of revenue surgeons active with add threshold XXX, majority of injuries ago. our AxoGen our one have our as the growth revenue total believe existing be our our we that accounts These have revenue of XXX
use to of surgeons the we year. our grown on Matters the repair campaigns digital efforts second online with surgeon surgeon discussing of In and injury we awareness. surgeons. of to X,XXX has their quarter timely deliver to to exited peripheral continue sales quarter, continue continued focus to community with to to market marketing customers email our pleased news We our The supplement in Nerve nerve and solutions. participate the first content nerve high over level important the continued targeted building now and half Turning as utilize of during our team the were our surgeon community, engagement the
and through also websites to successfully We XXXX. during do visits to marketing patients were increased of successfully rethinkpain.com awareness repair which nerve resensation.com campaigns, our continue increase with first our which of the half direct-to-patient –
than education in certain to second for As repair. leaders of more the as to second leader fellows. invest in We're virtual of events return program remain annual education in microsurgery providing combination And education off fellowship in prior programs hand XXXX to series continue programs. of hands-on emerging class nerve We a We and currently nerve the virtual kicked five in in-person of and scheduled development. of half the of a labs fellows class advocacy years, for and repair, education three in-person and each the we XXXX. planning April, to training committed a quarters safe we've with providing through Masterminds events of local, our trained
we the following completion products, fellowship, pleased hand the and to new attendings fellowship practice the of nerve I'm provide their XXXX their for class from have surgeon repair the our Beyond transition of performed surgery majority support training. using cases
return of in the the for educational As American we surgeon offering at San carefully Francisco. September, Annual to Society Surgery the Meeting live we'll Conference XXth a program, be the Hand upcoming the in of event
upper and through Our trauma case experiences, discussion. will categorical extremity practical and explore along solutions hands-on lab with for review lecture,
portfolio product evidence adoption. continue support surgeon to our of our We clinical in expand and increasing body of
statistically is MATCH for Nerve nerve decision-making. Avance in those X,XXX over analysis Our were Graft MATCH in than a RANGER of important comparable to surgeons, programs and enroll In that the and play enrolled with RANGER, role for conduit registries which RANGER. comparative clinical Data informing continues clinical of subjects these autograft from XXXX, demonstrated to two autograft. were to continue population outcomes now and conduit, repairs an better registry,
XXXX. Our RECON study remains of XXX completing in July subjects enrollment on of schedule after
nerve of especially the the University, these resulting And in of XXXX. pain. Two and address clinicians referring and of helps referrals of and associated on management follow-up the the the second Washington study, underway product of negative and and a a completed are reduction Nerve patient data with we treatment will pain. of surgical to managing growing quality Institute surgical X study our publications XXX well recent Washington treatment data graft injuries. world QX BLA the product. neuroma transition will XXXX, progressing and Cap we in study from Enrollment coming This visit by Phase expected REPOSE, enrollment occur to our of filing which the license section nerve for is life burden, to Both economic then section to This of well can that readout on comparative chronic Nerve surgical between XXX our overall advanced standard study conventional in study bring economic reminder, life. a treatment chronic significantly of impact for collaboration from manuscripts burden anticipate Axoguard be quarter the these the the in life pivotal nerve of our or to patient expect top readout XXXX. inform is phase of data to symptomatic our final the weeks. timely the peripheral tissue to of XXXX of the surgery supporting the in with nerve pain. significant BLA, in pain non-surgical RECON line a and followed is biologics and nerve surgeons associated QX be role quality compared now As biological application Finding intervention in A compared improve chronic is
slowly, As investing the we nerve evidence clinical repair impactful to and regulators times payers follow-up gather in regenerate provide to clinical data to of often decisions. advanced necessary portfolio. have nerve clinical utility the science come when time the and on effects meaningful resources Nerves making surgeons, our care the necessitates and which expect, assess we committed that remained long treatment repair, meaningful and to
registry many periods of the take for for the changes In solutions. began studies have amount repair. Our The months to enrollment conduct have clinical our XX of obtaining and like up up evidence nerve to ago. to RANGER, the the established reimbursement nerve an expertise research on study proposed enrollment nerve. to assessment approximately XX highlight RECON time, significant fully nerve nerve of repair years graft. RECON repair six more supporting clinical follow the effort to we performance body of demonstrate the of began impact advanced clinical to to XXXX. ago, required CMS outpatient years and utility and a We're appreciate the evidence committed remain to rates than the and and injuries range fortunate in peripheral I'd comment of the of And moment RANGER in safety, setting
procedures. repair for modest the at increases approximately most While proposed across XXXX X% nerve are
increase to implant. repairs continue for over an the last the utilizing with pleased be three We significant years
repairs a we to well represent support patients in Medicare nerve percentage with sites And of our repair center in product simple Commercial cases. of surgical feasible we of full These surgery follow economically changes the lead setting. While believe of ambulatory nerve portfolio payers positioned relatively small trauma all are the CMS. often reimbursement care. make
will to clinical over call past to mission combined outlook including our data a the to our nerve repair. spend in I adoption our discussing continue guidance. the the and to Before over We're scientific we I'd continue growth our updated like our our XXXX turn with revolutionize for confident investments Pete, financial commercial as decade moment substantial surgeon that execution long-term support
results, the XXXX million expect above of remain to full million continue range our the of in that On range expect year full the we're to strength XX%. This million $XXX We versus guide $XXX first the year $XXX.X to margin optimism for we prior financial guidance reflects our And now increasing year. half to million. of $XXX.X be our business. the will gross in
to As the variants we capacity. volumes monitor of continue and on impact COVID surgical procedure
As Pete? and we few growth to revenue look a company, the the turn beyond, annual forward sustainable low-XX%. to growth as I'll for to highlights. – long-term the now Pete in view review for financial to high call XXXX continue we of delivering a AxoGen teens over
